On the relationship between drug and carrier deposition from dry powder inhalers in vitro

International Journal of Pharmaceutics

Volumn 167, Issue 1-2, 1998, Pages 13-23

  Srichana, T ^a   Martin, G P ^a   Marriott, C ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Dry powder inhaler; Lactose; Mass median aerodynamic diameter; Salbutamol

Indexed keywords

DRUG CARRIER; LACTOSE; SALBUTAMOL SULFATE;

AIRFLOW; ARTICLE; DRUG CAPSULE; DRUG FORMULATION; DRY POWDER; FLOW RATE; IN VITRO STUDY; PARTICLE SIZE; POWDER INHALER; PRIORITY JOURNAL;

EID: 0032102794     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(98)00037-4     Document Type: Article

References (19)

1. Carstensen, J.T., 1977. Pharmaceutics of Solids and Solid Dosage Forms, Wiley, New York, pp. 147-148.
2. Clark A.R. The use of laser diffraction for the evaluation of the aerosol clouds generated by medical nebulizers. Int. J. Pharm. 115:1995;69-78.
3. Clay M.M., Pavia D., Clarke S.W. Effect of aerosol particle size on bronchodilation with nebulised terbutaline in asthmatic subjects. Thorax. 41:1990;364-368.
4. De Boer A.H., Gjaltema D., Hagedoorn P. Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers. Part 2: effect of peak flow rate (PIFR) and inspiration time on commercial dry powder inhalers. Int. J. Pharm. 138:1996;45-56.
5. French D.L., Edwards D.A., Niven R.W. The influence of formulation on emission, deaggregation and deposition of dry powders for inhalation. J. Aerosol Sci. 27:1996;769-783.
6. Ganderton, D., Kassem, N.M., 1992. Dry powder inhalers. In: Ganderton, D., Jones, T. (Eds.), Advances in Pharmaceutical Sciences, vol. 6, Academic Press, London, pp. 165-191.
7. Hickey A.J., Concession N.M., Van Oort N.M., Platz R.M. Factors influencing the dispersion of dry powders as aerosols. Pharm. Tech. 8:1994;58-82.
8. Hindle M., Byron P.R. Dose emissions from marketed dry powder inhalers. Int. J. Pharm. 116:1995;169-177.
9. Hindle M., Jashnani R.N., Byron P.R. Dose emissions from marketed inhalers: influence of flow, volume and environment. Respir. Drug Deliv. 4:1994;137-142.
10. Malton A., Sumby B.S., Dandiker Y. A comparison of in vitro drug delivery from salbutamol Diskus and terbutaline Turbuhaler inhaler. J. Pharm. Med. 6:1996;35-48.
11. Newman S.P., Moren F., Trofast E., Talaee N., Clarke S.W. Terbutaline sulphate Turbuhaler: effect of inhaler flow rate on drug deposition and efficacy. Int. J. Pharm. 74:1991;209-213.
12. Pitcairn G., Lunghetti G., Ventura P., Newman S.W. A comparison of the lung deposition of salbutamol inhaled from a new dry powder inhaler at two inhaled flow rates. Int. J. Pharm. 102:1994;11-18.
13. Ree P.J., Clark T.I.J., Moren F. The importance of particle size in response to inhaled brochodilators. Eur. J. Respir. Dis. 63:1982;73-78.
14. Ross D.L., Schultz R.K. Effect of inhalation flow rate on the dosing characteristics of dry powder inhaler (DPI) and metered dose inhaler (MDI) products. J. Aerosol Med. 9:1996;215-226.
15. Srichana T., Martin G.P., Marriott C. The effect of device design on drug deposition from dry powder inhaler formulations determined in vitro at different flow rates. Proc. Drug Deliv. Lungs, Aerosol Soc. Bristol. 7:1996;36-39.
16. Staniforth J.N., Rees J.E., Lai F.K., Hersey J.A. Interparticle forces in binary and ternary ordered powder mixes. J. Pharm. Pharmacol. 34:1982;141-145.
17. Vidgren M., Vidgren P., Uotila J., Paronen P. In vitro inhalation of disodium cromoglycate powders using two dosage forms. Acta Pharm. Fenn. 97:1988;187-195.
18. Zanen P., van Spiegel P.I., van der Kolk H., Tudhuizen E., Enthoven R. The effect of the inhalation flow on the performance of a dry powder inhalation system. Int. J. Pharm. 81:1992;83-91.
19. Zeng X.M., Tee S.K., Martin G.P., Marriott C. Effects of mixing procedure and particle size distribution of carrier particle on the deposition of salbutamol sulphate from dry powder inhaler formulations. Proc. Drug Deliv. Lungs, Aerosol Soc. Bristol. 7:1996;40-43.